CYTK analyst estimates
Cytokinetics (CYTK) analyst ratings, the average price target and its range, and every firm's latest call.
CYTK analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 14, 2026 | UBS | Cytokinetics (CYTK) PT Lowered to $104 at UBS | $104.00 |
| Oct 8, 2026 | RBC Capital | Cytokinetics price target raised to $113 from $112 at RBC Capital | $113.00 |
| Aug 13, 2026 | Barclays | Cytokinetics price target raised to $110 from $95 at Barclays | $110.00 |
| Aug 10, 2026 | Truist Financial | Cytokinetics price target raised to $112 from $106 at Truist | $112.00 |
| Aug 7, 2026 | RBC Capital | Cytokinetics price target lowered to $112 from $117 at RBC Capital | $112.00 |
| Aug 7, 2026 | Needham | Cytokinetics price target raised to $112 from $102 at Needham | $112.00 |
| Jul 7, 2026 | RBC Capital | Cytokinetics price target lowered to $117 from $119 at RBC Capital | $117.00 |
| Jun 29, 2026 | UBS | Cytokinetics upgraded to Buy from Neutral at UBS | $115.00 |
| Jun 24, 2026 | Mizuho Securities | Cytokinetics price target raised to $118 from $100 at Mizuho | $118.00 |
| Jun 17, 2026 | RBC Capital | RBC Capital on Cytokinetics (CYTK): 'The stock is significantly undervalued despite today's move' | $119.00 |
| May 11, 2026 | H.C. Wainwright | Cytokinetics price target raised to $140 from $136 at H.C. Wainwright | $140.00 |
| May 6, 2026 | Stifel Nicolaus | Cytokinetics price target raised to $108 from $98 at Stifel | $108.00 |
| May 6, 2026 | UBS | Cytokinetics price target raised to $119 from $101 at RBC Capital | $119.00 |
| May 6, 2026 | Morgan Stanley | Cytokinetics price target raised to $103 from $90 at Morgan Stanley | $103.00 |
| May 5, 2026 | Truist Financial | Cytokinetics price target raised to $106 from $92 at Truist | $106.00 |
- 17 firms rate CYTK: 17 buy, 0 hold, 0 sell.
- The average price target is $113.33 from 9 analysts, from $103.00 to $140.00.
Updated 2026-11-02 23:12 UTC